Sheikh M, et al. Current status and future prospects for esophageal cancer. Cancers. 2023;15(3):765.

Liang H, Fan JH, Qiao YL. Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol Med. 2017;14(1):33–41.

Article  PubMed  PubMed Central  Google Scholar 

Li B, et al. Trends of esophageal cancer incidence and mortality and its influencing factors in China. Risk Manag Healthc Policy. 2021;14:4809–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He S, et al. Advances and challenges in the treatment of esophageal cancer. Acta Pharm Sin B. 2021;11(11):3379–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang Y, et al. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111–22.

Article  PubMed  PubMed Central  Google Scholar 

Jiang X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10.

Article  PubMed  PubMed Central  Google Scholar 

Li R, et al. Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment. Front Oncol. 2022;12:1096717.

Article  CAS  PubMed  Google Scholar 

Vrana D, et al. From tumor immunology to immunotherapy in gastric and esophageal cancer. Int J Mol Sci. 2018;20(1):13.

Yang C, Chen K. Long non-coding rna in esophageal cancer: a review of research progress. Pathol Oncol Res. 2022;28:1610140.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang G, et al. FOXP4-AS1 may be a potential prognostic biomarker in human cancers: a meta-analysis and bioinformatics analysis. Front Oncol. 2022;12:799265.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niu Y, et al. LncRNA FOXP4-AS1 promotes the progression of esophageal squamous cell carcinoma by interacting with MLL2/H3K4me3 to upregulate FOXP4. Front Oncol. 2021;11:773864.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, et al. YY1-induced upregulation of FOXP4-AS1 and FOXP4 promote the proliferation of esophageal squamous cell carcinoma cells. Cell Biol Int. 2020;44(7):1447–57.

Article  CAS  PubMed  Google Scholar 

Jiang X, Chen ZJ. The role of ubiquitylation in immune defence and pathogen evasion. Nat Rev Immunol. 2011;12(1):35–48.

Article  PubMed  Google Scholar 

Deng L, et al. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5(1):11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun T, Liu Z, Yang Q. The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer. 2020;19(1):146.

Article  PubMed  PubMed Central  Google Scholar 

Cao YF, et al. Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma. Cell Death Differ. 2023;30(2):527–43.

Article  CAS  PubMed  Google Scholar 

Borgmann M, Quante M. Impact of the tumor microenvironment for esophageal tumor development-an opportunity for prevention?. Cancers. 2022;14(9):2246.

Zheng Y, et al. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nat Commun. 2020;11(1):6268.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liao C, et al. Long non-coding RNA FOXP4-AS1 is a prognostic biomarker and associated with immune infiltrates in ovarian serous cystadenocarcinoma. Medicine. 2021;100(40):e27473.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Poondla N, et al. Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities? BMB Rep. 2019;52(3):181–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tao L, et al. USP10 as a potential therapeutic target in human cancers. Genes. 2022;13(5):831.

Gao D, et al. The Prognostic Value and Immune Infiltration of USP10 in Pan-Cancer: A Potential Therapeutic Target. Front Oncol. 2022;12:829705.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Naimi A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20(1):44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen L, et al. PD-L1 expression promotes epithelial to mesenchymal transition in human esophageal cancer. Cell Physiol Biochem. 2017;42(6):2267–80.

Article  CAS  PubMed  Google Scholar 

Xu J, et al. Evidence that dysplasia related microRNAs in Barrett’s esophagus target PD-L1 expression and contribute to the development of esophageal adenocarcinoma. Aging. 2020;12(17):17062–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang H, et al. Exosomal PD-L1 confers chemoresistance and promotes tumorigenic properties in esophageal cancer cells via upregulating STAT3/miR-21. Gene Ther. 2023;30(1–2):88–100.

Article  CAS  PubMed  Google Scholar